BCL2 and diffuse large B-cell lymphoma: In addition to the COO-based approach, more recent studies have reported that DLBCL with BCL2 and MYC abnormalities, such as double-expressor and double-hit lymphoma, is associated with more aggressive clinical course and a poor survival outcome6–9.